Pfizer Inc.


Latest Trade






Today's Range




52 Week Range




As of on the New York Stock Exchange ∙ Minimum 15 minute delay


Previous Close
3M AVG Volume
Today's High
Today's Low
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Forward P/E
Dividend (Yield %)

Next Event

Q3 2019 Pfizer Inc Earnings Release

Latest Developments


Merck KGaA: Positive EU Opinion On Avelumab For Renal Cell Cancer

Health Canada Advises Canadians To Exercise Caution When Taking Gabapentin Or Pregabalin With Opioids

Pfizer Announces Positive Preliminary Results From Phase 2 Study 20-Valent Pneumococcal Conjugate Vaccine


About Pfizer Inc.

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.


Biotechnology & Drugs

Contact Info

235 E 42ND ST


Executive Leadership

Ian C. Read

Executive Chairman of the Board

Albert Bourla

Chief Executive Officer, Director

Frank A. D'Amelio

Chief Financial Officer, Executive Vice President - Business Operations

Mikael G. Dolsten

President - Worldwide Research and Development

Michael Goettler

Group President - Pfizer Upjohn

Key Stats

2.54 mean rating - 13 analysts
Revenue (MM, USD)
















Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)

Latest News

UPDATE 1-Novartis joins Pfizer with FDA fast-track tag for lung cancer hopeful

Novartis has nabbed the U.S. Food and Drug Administration's breakthrough therapy designation for its experimental medicine capmatinib as it joins Pfizer in the race to treat a tough-to-treat mutated lung cancer type.

Pfizer invests $500 million in expanding gene therapy facility

Pfizer Inc is investing $500 million to expand a manufacturing facility in Sanford, North Carolina, that plays a central role in its efforts to become a major player in gene therapy, the company said on Wednesday.

Eli Lilly wins Fed Circuit decision fending off generic Alimta

Eli Lilly and Company won a federal appeals court decision on Friday that protects its chemotherapy drug Alimta from generic competition from Pfizer Inc and Dr Reddy's Laboratories Ltd.

Case to Watch: NLRB to decide if gag clause in Pfizer's arbitration agreements is legal

Pfizer Inc is urging the National Labor Relations Board to rule that a U.S. Supreme Court decision that said class-action waivers in employee arbitration agreements do not violate workers' rights to organize also applies to confidentiality clauses in the pacts.

UPDATE 2-J&J says FTC probing efforts to protect arthritis drug Remicade

The Federal Trade Commission issued civil subpoenas to Johnson and Johnson in June as part of an investigation into whether contracting practices for its blockbuster rheumatoid arthritis drug, Remicade, violated antitrust laws, the company said in a regulatory filing on...

Mylan deal puts future of its beleaguered EpiPen in spotlight

Mylan NV's <MYL.O> planned merger with Pfizer Inc's <PFE.N> off-patent branded drugs business may have boosted its share price on Monday, but one of its most pressing problems remains: shortages of its flagship EpiPen emergency allergy treatment.

Deals of the day-Mergers and acquisitions

The following bids, mergers, acquisitions and disposals were reported by 2025 GMT on Monday:

Pfizer to spinoff, merge off-patent drugs unit with Mylan

Pfizer Inc <PFE.N> has agreed to spin off its off-patent branded drugs business and combine it with generic drugmaker Mylan NV <MYL.O>, a move that leaves Pfizer with its more profitable innovative drugs, including cancer treatment Ibrance and pneumonia vaccine Prevnar.

Pfizer in talks to transition EpiPen manufacturing into generics spinoff

Pfizer Inc is in talks to merge its contract manufacturer that produces Mylan's EpiPen emergency allergy treatment into the new generics business it has created by combining its older off-patent medicines unit with generic drugmaker Mylan NV, a Pfizer spokeswoman said.

Pfizer posts 30% rise in quarterly profit

Pfizer Inc <PFE.N> on Monday reported a 30% rise in quarterly profit, helped by demand for its branded treatments such as Ibrance, Eliquis and Xeljanz.

Mylan to combine with Pfizer's off-patent medicines unit

Mylan NV said on Monday it would combine with Pfizer Inc's off-patent branded and generic established medicines business to form a global generic drugmaker.

Pfizer in talks to merge off-patent drugs business with Mylan: source

Pfizer Inc <PFE.N> is in talks to merge its off-patent drugs business with Mylan NV <MYL.O> in a stock deal, according to a source familiar with the matter.

Pfizer in talks to merge off-patent drugs business with Mylan

Pfizer Inc is in talks to merge its off-patent drugs business with Mylan NV in a stock deal, the Wall Street Journal reported on Saturday, citing people familiar with the matter.

Pfizer's Wyeth loses bid to duck hormone-therapy lawsuit

Pfizer Inc's Wyeth unit must face a class action alleging that the drugmaker misled California women by downplaying risks including breast cancer associated with its hormone-replacement therapy products, a federal judge has ruled.

Senator Warren asks former FDA chief Gottlieb to resign from Pfizer board

U.S. Senator Elizabeth Warren urged former U.S. Food and Drug Administration Commissioner Scott Gottlieb to immediately step down from Pfizer Inc's <PFE.N> board, three months after his departure from the health regulator.

Pfizer, Sanofi, to boost South African Biovac's vaccine output

South Africa's Biovac Institute will start local production of Sanofi's Hexaxim vaccine next year and Pfizer's anti-pneumonia Prevnar 13 vaccine in 2021, boosting supply of life-saving drugs in its main market, its CEO said.

GSK-Pfizer joint venture gets conditional approval from South Africa's competition regulator

GlaxoSmithKline Plc <GSK.L> and Pfizer Inc's <PFE.N> planned joint venture received conditional approval from a South African regulator on Tuesday, clearing a hurdle in the creation of a consumer health giant with sales of 9.8 billion pounds ($12.38 billion).

Pfizer, Sanofi, to boost South African Biovac's vaccine output

South Africa's Biovac Institute will start local production of Sanofi's Hexavalent vaccine next year and Pfizer's anti-pneumonia Prevnar 13 vaccine in 2021, boosting supply of life-saving drugs in its main market, its CEO said.

Sarepta surges after Pfizer gene therapy data raises safety concerns

Shares of Sarepta Therapeutics Inc <SRPT.O> surged 15% on Friday after some safety concerns were raised in a small, early-stage study of a competing gene therapy for a rare muscle-wasting disorder from Pfizer Inc <PFE.N>.

Pfizer gene therapy for rare muscle disease shows promise in small, early study

Pfizer Inc on Friday presented promising results from a tiny early study of its experimental gene therapy for a rare muscle disease, but two of the six patients in the trial experienced side effects that landed them in the hospital.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.